SOLO Shares Jump 19% end of day today. Still a Buy?

SOLO

SOLO Shares jump 19% end of day. Is it still a buy? 

SOLOShares of SOLO or Electra Meccanica jumped  on Thursday by more than 19% and closed at $9.48pps, after an article was released of Improved Sales Visibility by SeekingAlpha. 

Shares of SOLO were already up more than 20% in January as the Electric car market has been on major run since Biden took office. 

Electrameccanica Vehicles Corp., a development-stage company, develops, manufactures, and sells electric vehicles in Canada. The company operates in two segments, Electric Vehicles and Custom Build Vehicles. Its flagship product is the SOLO, a single seat vehicle. The company is also developing Super SOLO, a sports car model; and Tofino, an all-electric two-seater roadster. It also develops and manufactures custom built vehicles. The company sells its vehicles online through electrameccanica.com Website, as well as through six retail stores. Electrameccanica Vehicles Corp. was founded in 2015 and is headquartered in Vancouver, Canada.

SOLO CHART

 

NTN Buzztime Announces Meeting with Shareholders. Stock Falls Sharply for second day.

PUDO

NTN Buzztime Announces Meeting with Shareholders. Stock Falls for second day.

NTN BuzztimeBuzztime has been moving uphill since September, and in last 45 days had some significant jumps. In mid September NTN was trading around $1.60pps and by end of January had hit highs above $5.20pps

That all ended in the last 2 days. Buzztime NTN fell on Wednesday this week by 20% intraday, from $6.38 to $4.82.

Just 2 hours after the market closed they released press and what was already a bad day got a bit worse. 

By Market open today NTN shares started trading at $4.55 and have stayed under $5 most of the day. 

NTN News -NTN Buzztime Announces Date of Special Meeting of Stockholders to Vote on Proposed Merger and Asset Sale

Another Breakout Stock Alert

 

Northern Dynasty Minerals (NAK) Buy or Sell?

NAK

Northern Dynasty Minerals Ltd (NAK) Buy or Sell?

One of the companies to have been in the news in recent weeks is Northern Dynasty Minerals Ltd (NAK) and much of that is due to its Alaska Pebble Mine project. That has resulted in a considerable rally in its stock as well.

Major News

Over the course of the past month, the stock has rallied strongly and delivered gains of as much as 80%. However, it should be noted that the stock has experienced considerable ups and downs ever since the United States Army Corps of Engineers rejected Northern Dynasty’s response with regards to environmental issues related to the above-mentioned project.

However, the rally in the recent days came about after Northern Dynasty announced that it lodge a request for appeal (RFA) with regards to the decision. In this regard, investors need to note that the rejections from the U.S. Army Corps of Engineers had almost been a death blow for the project in question.

That being said, the company’s CEO stated that the new RFA lodged by Northern Dynasty apparently contains strong arguments that suggest that the rejection from the Army Corps of Engineers may have been against the law. Hence, it is no surprise that the recent development has resulted in considerable excitement among investors with regard to the Northern Dynasty stock.

The RFA was actually sent by the company back on January 19 but the details of the same emerged around a week later. The RFA has argued that the concerns that have been raised with regards to the project could have been resolved if the company had been provided an opportunity to address them.

In addition to that, Northern Dynasty also asserted that in addition to not getting the opportunity to address the issues, the company was not even provided any explanation regarding the reasons behind such an action. Investors have sent the stock higher in the hope that the project might be resurrected. It remains to be seen how the stock performs this week. 

Start your own Due Diligence with the following links 

Company Website

Yahoo finance Page 

Recent News

Other Breakout Stocks 

Oculus VisionTech Inc (OTCMKTS-OVTZ) Stock Heats Up 250%

Oculus Visiontech OVTZ

Oculus VisionTech Inc (OTCMKTS-OVTZ) Stock Heats Up: Soars 250% in 6-Week

Cybersecurity is an industry that has grown at a remarkable pace over the past few years and nowadays, investors actively looking for ways to get into that sector. Over the past few weeks, the Oculus VisionTech Inc (OTCMKTS-OVTZ) stock has emerged as one of the possible options owing to the sort of gains its stock has generated.

Major News

In the past six weeks, the Oculus stock has generated gains of as much as 250%, and perhaps it is time for investors to take a closer look at the company. Oculus is a cybersecurity company that is focused on developing products that protect digital piracy of documents.

Breakout News on FCTI Click Here 

It is primarily focused on the compliance and data governance markets. Back in November last year, the company announced the alpha release of its product named ‘Forget Me Yes’. The product in question is a data privacy compliance platform. It is a unique product and it is no surprise that it led to considerable buzz around the Oculus stock in the markets.

‘Forget Me Yes’ is a SaaS (software as a service) API platform. It is meant for compliance with regards to the right to be forgotten and the right of erasing of both individuals as well as organizations. The platform helps in structuring the data in compliance with the California Consumer Privacy Act.

However, that is not the only product that Oculus can boast of. The company has used its proprietary technology and built a system that helps in embedding digital watermarking for video on-demand clients. On the other hand, the company is also known for its cloud-powered system that helps in protecting documents through digital watermarking.

At a time when piracy is rampant, Oculus helps in providing protection to documents, images, and videos. The company is based out of Vancouver, Canada, and could be in the radars of investors over the coming days.

Fact Inc Adding Heavyweights to its Board of Directors OTC-FCTI

FCTI

        Fact Inc.  just started trading under the ticker (OTC: FCTI), and has immediately made some major additions to its team, showing the public and its investors that it is focused on putting an end to art fraud.  

Click here to read recent article on Fact Inc

  • Today, February 2nd 2021 Fact Inc. (OTC: FCTI) Announced that internationally recognized curator and art expert, Jean-David Malat, has joined its Advisory  Board. 

Read Press here

[caption id="attachment_9001" align="alignleft" width="255"]FCTI Fact Inc Fact Inc Jean David Malat[/caption]
 “Mr. Malat is one of the world’s most respected and influential art dealers, described as ‘the best connected man in London’ by ​The Times, and ‘London’s most in demand guru’ by Metro Newspaper. For more than 15 years he has built a clientele of high-profile clients, including Kate Moss, Bono and Madonna.  Born in Paris and now in the UK, Mr. Malat trained at Sotheby’s, established in 1744 and now the world’s largest, most trusted and dynamic marketplace for fine art, jewelry and collectables spanning 40 countries. During the early years of his career, Mr. Malat curated impressive collections with the collaboration of various world famous museums and foundations such as The Heydar Aliyev Center in Azerbaijan. In 2007, he redesigned the art-on-display for the opening of the Théâtre Mogador in Paris, and the following year achieved a significant career milestone, acquiring and selling two late-period Picasso paintings in the middle of the 2008 Recession.”

 

  •  On the 14th of January Fact Inc. (OTC:FCTI) Announced that former U.S. Assistant Secretary of Homeland Security Julie Myers Wood had joined its Board of Directors.

Read Press Here

[caption id="attachment_9002" align="alignleft" width="195"]FCTI Fact Inc Fact Inc Julie Myers Wood[/caption]
“Ms. Wood is an esteemed regulatory compliance and security expert with over 25 years of achievements in the public, private and political sectors. After graduating from Cornell Law School, Ms. Wood began her career as a lawyer at leading firm Mayer, Brown & Platt in Chicago. Her career has been focused on regulatory and enforcement issues through her various roles including defense counsel, government investigator, federal prosecutor, and compliance consultant.”
 
 
Fact Inc. Company Description

Fact, Inc. (OTC:FCTI) focuses on developing forensic technology for the art and collectibles market. The company is developing a front-end user interface, as well as modifying existing ballistics firmware for a comprehensive verification, tracking, and reporting system. Using white light interferometry, FACT takes a non-destructive 3D digital fingerprint of the art using approximately 100,000 unique images. It offers a suite of products that include authentication, condition reporting, GPS tracking, and provenance data, as well as collection management stored on blockchain accessible in real time to the consumer. The company’s software application is applicable to various channels in the fine art and collectible industry, including S secured lending, insurance, dealers, auction houses, and grading companies. The company was formerly known as Tiburon International Trading Corp. and changed its name to Fact, Inc. in November 2020. FACT, Inc. is headquartered in Toronto, Canada. As of October 5, 2020, Fact, Inc. operates as a subsidiary of Kryptos Art Technologies, Inc.

Disclaimer :​Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).We publish the Information on our website, smallcapexclusive.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, FACT, Inc. Small Cap Exclusive has been hired by FACT, Inc. for a period beginning on November 13, 2020 to publicly disseminate information about (FCTI) via website and email. We have been compensated $51,000. We will update any changes to our compensation.

​Read full disclaimer here.

ESPR Esperion Therapeutics, Inc. Consolidation (NASDAQ:ESPR)

espr stock

(NASDAQ:ESPR) Esperion Therapeutics Inc

 

(NASDAQ:ESPR) Esperion Therapeutics, Inc. peaked out and closed at $48.90, way up from about $10 where it sat last August, but way below its all-time high of $107.51 in spring 2015. Still, ESPR has been on a good run since about January, but especially since June, probably based on positive news coming out on various stages of ongoing clinical trials. ESPR is a pharmaceutical company based in Ann Arbor, MI and dedicated pretty much exclusively to developing non-statin LDL cholesterol drugs with safer profiles and fewer side effects than the statins currently on the market.

espr stock

THE COMPANY
ESPR Esperion Therapeutics Inc. has an interesting history, having been acquired by Phizer in 2004 for $1.3Bn in order to get sole possession of an experimental statin called ETC-216 and prevent their competitors from obtaining it. Esperion was founded by Dr. Roger Newton, the man responsible for co-discovering the Lipitor molecule, a statin drug and the most prescribed medication in the history of pharmaceuticals. Phizer eventually killed off the research and ESPR was re-acquired by Dr. Newton after he raised the capital to buy the rights to the name and to their other experimental compound, ETC-1002, which is also a novel cholesterol treatment based on the biological properties of bempedoic acid, which is converted to ETC-1002-CoA in the human liver and, through a sequence of reactions, results in the liver’s removal of LDL-C from the blood.

ESPR has pushed bempedoic acid in 18 completed Phase 1 and Phase 2 clinical studies and it is currently being evaluated in four other Phase 3 LDL efficacy and safety studies, along with one cardiovascular outcomes trial. Their pipeline consists solely of Bempedoic Acid (once daily pill) and a combination of Bempedoic Acid and Ezetimibe (once daily pill) which itself just began Phase 3 trials.

ESPR stock price has fluctuated greatly in the past 52-week period with a range of $9.40 to $57.38 and earlier in August they announced an underwritten offering of 3,100,000 shares to the public at $49.00 per with the goal of continuing to finance the previously mentioned clinical trials for the two drugs in their pipeline. There’s lots of detailed technical information out there on these trials, but suffice it to say that if any one or a combination of them are unqualified successes, they could be looking at blockbuster status on par with or even bigger than Lipitor and of course a huge uptick in value. Results are somewhat far off, however, with expected announcements after the completion of the studies in Q2 and Q3 2018 and various bridging studies yet to begin. Of note, ESPR’s R&D budget for the first six months of 2017 was $74.1M compared to $19.5M for the same period in 2016.

We think this makes ESPR an intriguing investment. With the FDA having approved an abbreviated regulatory pathway to the bempedoic acid/ezetimibe combination, and a looming New Drug Application anticipated after the studies are concluded in 2018, this stock may take a slight dive in the next few weeks, but rally significantly toward its $107.51 all-time high by the end of 2018.

FCBK Receives Business Enterprise Award

fcbk stock news

CERRITOS, Calif.–(BUSINESS WIRE)–First Choice Bank (OTCQX: FCBK) (the “Bank”) is honored to be recognized once again for the Community Development Financial Institution (CDFI) Fund’s Business Enterprise Award. The Bank has been a recipient every year since 2011.

Editors Comment : FCBK current ppc is $23.50, with very low daily volume. Don’t expect to see much change over the near future.

The Bank is pleased that its commitment and dedication to financing and supporting community activities, especially for low and moderate income communities, is recognized by the US Treasury Department’s CDFI. The CDFI’s 2016 grant award recognizes and rewards the Bank’s continuing efforts to increase its lending and service activities within the economically distressed communities that the Bank serves.

First Choice Bank is a community focused financial institution serving diverse consumers and commercial clients, as a CDFI bank. Peter Hui, the Bank’s Chairman, said, “We are very proud of all of our efforts to make our community prosper. It is gratifying to receive this award as recognition of that commitment.”

FCBK

ABOUT FIRST CHOICE BANK

First Choice Bank, headquartered in Cerritos, California, is a community focused financial institution, serving diverse consumers and commercial clients and specializing in loans to small businesses, Private Banking clients, Commercial and Industrial (C&I) loans, and commercial real estate loans with a niche in providing finance for the hospitality industry. The Bank is a Preferred Small Business Administration (SBA) Lender. Founded in 2005, First Choice Bank has quickly become a leading provider of financial services that enable our customers to grow, maintain strength, and reach unprecedented levels of success. We strive to surpass our clients’ expectations through our efficiency and professionalism and are committed to being “First in Speed, Service, and Solutions.” First Choice Bank stock is traded on the Over the Counter (OTCQX); our Ticker Symbol is FCBK.

The Bank’s web site is www.FirstChoiceBankCA.com.

 

Click For Disclaimer

ABBV AbbVie Inc Continues To Impress (NYSE:ABBV)

abbv

Intro & History on ABBV (NYSE:ABBV) : 

 

In the biotech and medical marijuana arena, we think that ABBV AbbVie Inc. (NYSE ABBV) is an interesting and well known stock to keep an eye on. ABBV is a pharmaceutical development, discovery, manufacturing and sales firm based in Illinois near Chicago, and traded on NYSE and they are, according to Wikipedia, the world’s eighth-largest independent biotech company by market cap. AbbVie falls squarely into the “Big Pharma” category. From their own company literature they are:

 

“…a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.  In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.”

Cara

AbbVie originated in 2013 when Abbott Laboratories decided to separate into two separately traded companies. Abbott is now focused only on medical devices, equipment and nutrition products whereas AbbVie is strictly in the pharmaceutical research and manufacturing business.

 

They manufacture several products, which in this day and age of ubiquitous pharma adverts, can arguably be called household names. The two most prominent of which – for our purposes anyway – are Humira and Marinol. Humira – This immunosuppressive drug accounts for over 60% of AbbVie’s revenue and is used to treat Crohn’s disease and happens to be the highest grossing drug *in the world*, with over 15% growth in the past year alone. There are so-called “patent cliff” concerns looming, but I’ll address those momentarily.   Marinol – This marijuana derivative, also known as Dronabinol, is marketed to chemotherapy, AIDS and other patients dealing with nausea, vomiting and suppressed appetite resulting from a pathology or treatment regimen. It is currently regulated as a Schedule III substance under the Controlled Substance Act, differing markedly from marijuana which sits at Schedule I and carries unreasonably harsh criminal penalties in many places in the United States and abroad. Medicinal cannabis/marijuana is currently approved in over half of the United States.

 

Recent News & Developments:

ABBV currently has an alphabet soup of promising experimental drugs in the hopper. The one drawing the most publicity is Upadictinib (formerly research chemical ABT-494) which recently significantly outperformed a placebo in clinical trials for rheumatoid arthritis. The FDA recently rejected Baricitinib (developed and submitted by Eli Lilly and Incyte) thereby seriously limiting competition for Upadictinib. Now all AbbVie has got to do is find a catchier name for Ubpadictnib it and send out the sales force. I kid, of course; if history is any indication, it could be named “Thistuffakillyatinib” and it wouldn’t make a bit of difference – so long as it continues to work without any previously unforeseen large scale side effects and the accompanying class actions cropping up.

 

The one big question mark at this point; and one which doesn’t have too many informed investors and biotech experts worried given the timeframe, is the expiration of Humira’s patent in 2022 and the introduction of competing drugs. Since ABBV derives so much of their current income from this product, it is of course incumbent on them to develop replacement revenue drivers between now and then. Again, most analysts with whom I am familiar are bullish on the likelihood that this will indeed happen.

 

Market Data & Performance:

During the last one-year period this Large Cap stock has fluctuated between $55.06 (low) and $73.67 (high) with an average volume of 5,560,234, a current volume of over 9,000,000 and higher than average yield. The characteristic zigzag graph indicates rallies and reactions over the past five years, but the stock has trended generally upward in every year for which data is available since 2012. To further belabor the point, almost every new peak or trough has been higher than the preceding peak or trough through time, and the line-of-best-fit has a definitively positive slope.   ABBV has used about 58% of free cash flow to cover their past four quarterly payments which isn’t ideal, but far from abnormal. Price closed at $73.18 on June 22, 2017 and is currently trending down, but only by about 1% on June 23. Other mostly current stats are as follows:

  • Market Cap: 469B
  • PE Ratio: 18.97
  • EPS: 3.86
  • 6% yield

 

The company released its first quarter 2017 financial results and outlook at the end of April and it contained the following statement:

AbbVie is confirming its GAAP diluted EPS guidance for the full-year 2017 of $4.55 to $4.65. AbbVie expects to deliver adjusted diluted EPS for the full-year 2017 of $5.44 to $5.54, representing growth of 13.9 percent at the mid-point. The company’s 2017 adjusted diluted EPS guidance excludes $0.89 per share of intangible asset amortization expense and other specified items.

 

Paying down of the relatively high debt load has not, and looks to continue to not be a priority, which could mean that the C-suite is confident in the likelihood of continued future growth.

 

Looking Ahead:

To those of you with a particular interest in the cannabis market sector, AbbVie has had Marinol since 1985 and has over 30 years of research into cannabinoid compounds. Several experts have speculated that one path away from ABBV disproportionately heavy reliance on Humira and the dangers associated with the impending collapse of its veritable monopoly, would be in medical marijuana derivatives – the market for which is in the process of moving from $5 Billion in 2015, to over $20 Billion by 2020.

 

Conclusion:

 

Humira is facing existential competition, but not anytime soon. Toward weaning themselves from Humira, ABBV acquired rights to ½ of sales of Imbruvica, a cancer drug, in 2015 and it is joined in their oncology drug portfolio by Venclexta another novel cancer treatment drug. There are, again, many more products in the research phase.

Even if there is an overall market correction in biotech, it would affect all such stocks equally and probably hit the smaller companies harder – and given the increasingly positive reception to relaxed medical (and recreational) marijuana laws and the tax revenues that decriminalization and legalization would bestow at the state and national levels, it would behoove AbbVie to seriously consider this market vertical for continued research, development, and acquisitions. They have the benefit of their extensive previous research and the notion that the DEA simply has to be trending toward totally re-scheduling marijuana (and its derivatives); and we feel like they can afford to be; actually – they NEED to be very aggressive in pursuing innovations in this market.

 

Further, given Humira’s continuing status as the #1 revenue grossing drug on the planet, the next 3 or so years look promising as a mid-term investment – depending on how proactive AbbVie can be in staking out aforementioned (or currently unannounced) new market footprint(s).   Overall, in our opinion, the lower AbbVie trends toward the $60-65 threshold, the better the mid-to-long term bargain for investors and the more closely it should be followed.

Skip to content